Ultragenyx Pharmaceutical Inc. (RARE) has 5 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 5 sales totalling $340K. Most recent filing: Sept. 15, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 15, 2026 | Huizenga Theodore Alan SVP, Chief Accounting Officer | −$17,410 | 1,283 | −2% | Yes | |
|
|
||||||
| Sept. 8, 2026 filed Sept. 3, 2026 | Huizenga Theodore Alan SVP, Chief Accounting Officer | −$2,252 | 161 | −0% | No | |
|
|
||||||
| Aug. 4, 2026 filed Aug. 3, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | −$47,348 | 1,900 | −2% | Yes | |
|
|
||||||
| Aug. 4, 2026 filed Aug. 3, 2026 | Horn Howard Chief Financial Officer | −$117,024 | 4,696 | −5% | Yes | |
|
|
||||||
| July 6, 2026 filed July 1, 2026 | Horn Howard Chief Financial Officer | −$155,645 | 4,698 | −4% | Yes | |
|
|
||||||
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free